A phase 1/2 trial of PE0116&PE0105 in advanced solid tumours, run by Shanghai HyaMab Biotech Co.,Ltd., now recruiting.
PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor is a phase 1/2 interventional study registered as NCT05801237 by Shanghai HyaMab Biotech Co.,Ltd., with 120 participants planned, started 2023-09-21 and due to reach its primary completion in 2026-09. Interventions recorded: PE0116&PE0105.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.